(85 g) provides 93% of the DV (22,27)
This enzymatic overactivity is strongly associated with obesity, insulin resistance, and metabolic syndrome
Supports oral administration viability
However, 24 patients did not complete the 90-day period due to various reasons: two patients started other intranasal medications, five voluntarily withdrew, nine were excluded by researchers for non-compliance, seven were lost to follow-up, and one patient died
Protocol: AOD 9604: 500mcg morning fasted BPC-157: 250-500mcg twice daily (morning and evening) BPC-157 accelerates healing and reduces inflammation, letting you train harder during your cut
These typically include: Redness and swelling at the injection location Mild pain or tenderness lasting 24-48 hours Bruising in sensitive individuals Itching or irritation that resolves spontaneously Research protocols using high-quality AOD 9604 peptide show lower rates of injection site reactions compared to studies using lower-grade compounds